US 11,753,401 B2
Polymorphs of Selinexor
Brian C. Austad, Tewksbury, MA (US); and David G. Roe, Rockwood (CA)
Assigned to Karyopharm Therapeutics Inc., Newton, MA (US)
Filed by Karyopharm Therapeutics Inc., Newton, MA (US)
Filed on Apr. 5, 2023, as Appl. No. 18/131,273.
Application 18/131,273 is a continuation of application No. 17/365,656, filed on Jul. 1, 2021.
Application 17/365,656 is a continuation of application No. 16/679,630, filed on Nov. 11, 2019, granted, now 11,078,190, issued on Aug. 3, 2021.
Application 16/679,630 is a continuation of application No. 15/503,319, granted, now 10,519,139, issued on Dec. 31, 2019, previously published as PCT/US2015/045395, filed on Aug. 14, 2015.
Claims priority of provisional application 62/038,069, filed on Aug. 15, 2014.
Prior Publication US 2023/0242516 A1, Aug. 3, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 403/12 (2006.01); A61K 31/497 (2006.01); A61P 35/00 (2006.01)
CPC C07D 403/12 (2013.01) [A61K 31/497 (2013.01); A61P 35/00 (2018.01); C07B 2200/13 (2013.01)] 23 Claims
 
1. A pharmaceutical composition comprising:
a crystalline form of a compound represented by Structural Formula I:

OG Complex Work Unit Chemistry
wherein the crystalline form is characterized by at least three X-ray powder diffraction peaks at 2θ angles selected from 4.4°, 19.9°, 21.3° and 22.0°,
and a pharmaceutically acceptable carrier.